TrueMark Investments LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 48.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,807 shares of the company's stock after purchasing an additional 11,399 shares during the quarter. Johnson & Johnson makes up 1.6% of TrueMark Investments LLC's portfolio, making the stock its 21st largest holding. TrueMark Investments LLC's holdings in Johnson & Johnson were worth $5,034,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 10.5% in the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after purchasing an additional 329,473 shares in the last quarter. United Bank lifted its stake in shares of Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company's stock valued at $614,000 after acquiring an additional 202 shares during the period. Algert Global LLC acquired a new stake in Johnson & Johnson in the third quarter worth about $721,000. Loomis Sayles & Co. L P grew its position in shares of Johnson & Johnson by 44.2% during the 3rd quarter. Loomis Sayles & Co. L P now owns 87,611 shares of the company's stock worth $14,198,000 after buying an additional 26,869 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Johnson & Johnson by 7.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,891,911 shares of the company's stock valued at $468,662,000 after acquiring an additional 205,789 shares during the last quarter. Institutional investors own 69.55% of the company's stock.
Johnson & Johnson Stock Up 0.4 %
Johnson & Johnson stock traded up $0.70 during mid-day trading on Friday, reaching $163.83. The company's stock had a trading volume of 3,055,357 shares, compared to its average volume of 7,609,223. The business's 50 day simple moving average is $158.35 and its 200 day simple moving average is $156.23. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market capitalization of $394.80 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the business earned $2.29 earnings per share. Johnson & Johnson's quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is presently 74.59%.
Insider Activity at Johnson & Johnson
In related news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on JNJ. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Barclays lifted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Finally, Raymond James decreased their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.
Get Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
